A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10
mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of
treatment in Asian subjects with moderate to severe chronic plaque psoriasis who are
candidates for systemic therapy or phototherapy.